According to Travere Therapeutics's latest financial reports the company's current earnings (TTM) are -$0.35 B. a decrease over its 2022 earnings that were of -$0.3 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 | -$0.35 B | 19.48% |
2022 | -$0.3 B | 62.83% |
2021 | -$0.18 B | -4.82% |
2020 | -$0.19 B | 28.91% |
2019 | -$0.15 B | 43.76% |
2018 | -$0.11 B | 74.54% |
2017 | -$58.37 M | 1.35% |
2016 | -$57.59 M | -154.6% |
2015 | $0.10 B | -192.83% |
2014 | -$0.12 B | 235.39% |
2013 | -$33.88 M | 226812.81% |
2012 | -$0.02 M | 1.92% |
2011 | -$0.02 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | -$0.19 B | -47.27% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | -$18.95 M | -94.58% | ๐บ๐ธ USA |